Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Glycoprotein – e.g. – mucins – proteoglycans – etc.
Reexamination Certificate
2001-01-12
2003-08-05
Low, Christopher S. F. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Glycoprotein, e.g., mucins, proteoglycans, etc.
C530S350000, C530S300000, C536S103000, C514S002600, C514S058000, C435S007500
Reexamination Certificate
active
06602988
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to therapies with pharmaceutically active substances with potentially high side-effects, which have to be transported in the blood and delivered to specific target cells without influencing healthy organs.
2. Information Disclosure Statement
Therapies with very effective pharmaceutically active substances e.g. with antimitotic properties for cancer therapy often suffer from the fact that healthy organs are damaged severely by the therapy. These side effects often make the use of certain therapies impossible even if the therapy would be effective in curing the diseased organ. Therefore it is desirable to achieve specific targeting of the pharmaceutically active substances to the diseased organ or cells, and moreover to inhibit the delivery of the pharmaceutically active substance to healthy organs. Often a localized application of the pharmaceutically active substance to the diseased site is not possible, but the pharmaceutically active substance has to be administered systemically through the blood stream and is accessible for the whole organism. One way to prevent this is to build complexes with carrier molecules that mediate an inert transport through the blood and selectively release the pharmaceutically active substance at the target site.
In patent description in Pat. Ser. No. 09/554,223 by Jörg G. Moser (published as WO 9924474) a method was introduced to detoxify pharmaceuticals with dangerous side effects by physical encapsulation into cyclodextrin [CD] oligomers with a relatively rigid spacer structure B.
Cyclodextrins are annular glucose polymers, which are called alpha, beta or gamma cyclodextrin depending on the number of glucose moieties present, namely for 6, 7 or 8, respectively. A lipophilic cavity exists in the center of a cyclodextrin, where lipophilic substances can be enclosed. This property of cyclodextrins can be used to render hydrophobic substances water soluble. Preferably cyclodextrin oligomers are able to encapsulate hydrophobic substances. The bridging structures or spacers between the cyclodextrins determine the distance between the cavities and thereby the size of the molecule that can be encapsulated. The spacer structures have to be rigid to ensure the correct orientation of the cyclodextrin moieties for the retention of the cavity structure. Therefore the spacer structures contain preferably chemical bonds that cannot rotate freely.
The protected molecule is released upon cleavage of either the cyclodextrins or the bridging structures between the cyclodextrins. The necessary destruction of the complex and the consequent liberation of the included pharmaceutically active substance at the target site can be effected easily by hydrolysis of the cyclodextrin by a specific enzyme (Moser Ser. '223) or preferably by destruction of the spacer B′. In both cases the affinity between pharmaceutically active substance and covering CD's ceases by 4 orders of magnitude, and the pharmaceutically active substance slips out of the complex into the next living cell. The synthesis of CD-dimers is well known (See, for example A. Rübner et al.
J. Inclin. Phenom.
27 69-84 (1997)). Antimitotics like taxanes can be encapsulated this way.
The targeting of the complex to the diseased organ, e.g. a tumor, can be mediated by specific antibodies, preferably by using the biotin-avidin (bAV) system. In particular, it has been tried to couple complexes from CD-dimers and pharmaceuticals with biotin-avidin (bAV) systems in order to connect the complex with biotinylated monoclonal antibodies (b-mAB's) and, thereby, to concentrate the complex specifically to xeno-transplanted tumours in nude mice. In these experiments, the effect was not statistically significant even though the administered concentrations were very high.
Therefore, it is object of the present invention to improve the effect of complexed pharmaceutically active substances by changing the structure of the spacer of the CD dimer in a way that the complex can be concentrated at the desired site and that the pharmaceutically active substance is released intracellularly where its action is mostly efficient. Moreover, inert transport of the pharmaceutically active substance through the blood is possible, contrary to the prior art.
BRIEF SUMMARY OF OBJECTIVES OF THE INVENTION
It is an object of the invention to provide cyclodextrin end capped structures connected by rigid spacer sequence to encapsulate pharmaceutically active substances, where the spacer sequence has a preselected breaking point, which is stable in blood but cleavable within cells.
It is another object of the present invention to use, as spacers, peptide structures that are not cleavable by the proteolytic enzymes in blood but are sensitive to intracellular enzymes.
It is a further object of the present invention to modify the peptide spacer with biotin residues in different positions to couple the complex via a biotin avidin system to specific antibodies and thereby target the complex to specific sites.
Briefly stated, the present invention provides a Rigidly spaced, cyclodextrin dimers having a preselected breaking point within the spacer sequence so as to controllably release the active pharmaceutically active substance only after it reaches the desired treatment site. These preselected breaking points are stable in blood but are cleavable within cells. In preferred embodiments, the cyclodextrin-pharmaceutically active substance complex is targeted to specific sites via incorporation of specific antibodies for the targeted sites, typically by complexing a biotin-avidin system to specific antibodies which thereby targets the complex to a specific site. Once at the site as the complex is taken up into the cell the preselected break point is cleaved within the cell and the encapsulated pharmaceutically active substance becomes available for action within the targeted cell. This approach permits the use of highly effective and efficient pharmaceutically active substances, whose safety restricts use to last chance efforts or which are unable to qualify for human use due to their potential side effects. In a preferred embodiment peptide structures are used as part of the spacers between bridged cyclodextrins The cyclodextrin oligomers are complexed with pharmaceuticals with potential high side effects to safely, efficiently achieve the therapeutic action desired.
The above and other objects, features and advantages of the present invention will become apparent from the following detailed description.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The essential element of the present invention is the provision of a preselected breaking point, which is stable in blood but cleavable within specific cells, in a system capable of transporting hydrophobic moieties through the blood stream. Once a targeted cell site is reached, the carrier system cleaves to provide access of the hydrophobic pharmaceutically active substance moiety in the cell to initiate therapeutic action as required by the medical treatment. Since the blood contains several proteolytic enzymes the breaking point is selected to only be sensitive to intracellular enzymes. The structure of the carrier system is preferably a cyclodextrin (CD) dimer with a rigid spacer separating the CD ends, wherein the length and other properties of the spacer are selected to allow capture and retention of a pharmaceutically active substance within the cavity formed between the ends. The preselected breaking point preferably is in the spacer structure along with moieties which may target the desired cell sites, where therapeutic action is required.
When a peptide structure is used as a spacer structure with breaking point, free lysine has to be avoided due to the frequent trypsin-like specificity of blood proteases. Intracellular proteases of the proteasomes contain chymotrypsin. A compatible sequence for the spacer is e.g.:
The preselected breaking point is labelled by the arrow (↑). Sequenc
Hoffmann Ralph
Moser Jörg G.
BJ Associates
CeramOptec Industries Inc.
Skutnik Bolesh J.
LandOfFree
Cyclodextrin dimers with spacers having peptide structures... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclodextrin dimers with spacers having peptide structures..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclodextrin dimers with spacers having peptide structures... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3091993